

December 15, 2003

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. GJE-207CD1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : John Gary Montana, Andrew Douglas Baxter, David Alan Owen, Robert
John Watson
Docket No. : GJE-207CD1
For : Hydroxamic and Carboxylic Acid Derivatives

Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent applications:

U.S. Serial No. 09/777,522, filed February 6, 2001; and

U.S. Serial No. 09/244,739, filed February 5, 1999, now abandoned.

The subject application claims the benefit under 35 USC §120 of the filing date of patent applications 09/777,522 and 09/244,739. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the 09/777,522 and 09/244,739 applications, as well as any references cited during the prosecution thereof, be made of record in the subject application. As copies of the references made of record in the 09/777,522 and 09/244,739 applications, and cited on the attached form PTO/SB/08, can be found in the 09/777,522 and 09/244,739 casefiles, copies of those references are not provided herewith.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRP/sl

Attachment: Form PTO/SB/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number		
			Filing Date December 15, 2003		
			First Named Inventor John Gary Montana		
			Art Unit		
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number GJE-207CD1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-5,932,595	08-03-1999	Bender <i>et al.</i>	All
	U2	US-6,187,924 B1	02-13-2001	Baxter <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)			
	F1	EP	0780386	06-25-1997		All
	F2	WO	96/35714	11-14-1996		All
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Application Number

Filing Date

December 15, 2003

First Named Inventor

John Gary Montana

Group Art Unit

Examiner Name

Attorney Docket Number

GJE-207CD1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	JANKOWSKI, K. <i>et al.</i> "Sur Les Oxathiane-1,4-one-2 *)" <i>Bulletin de L'Academie Polonaise Des Sciences</i> , 1971, pp. 661-672, Vol. 19, Nos. 11-12, English summary.	
	R2	WITIAK, DONALD T. <i>et al.</i> "cis- and trans-2-Mercaptocyclobutylamines. Synthesis and Antilipolytic Properties in Vitro" <i>Journal of Medicinal Chemistry</i> , 1972, pp. 803-808, Vol. 15, Vol. 8.	
	R3	ROITT, I. M. <i>et al.</i> "Encyclopedia of Immunology", Autoimmune Diseases, 1993, pp. 195-201, Academic Press, Harcourt Brace Jovanovich, publishers.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.